De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Lupin Beheer

Beheer criteriumcontroles 2/4

De CEO Lupin's is Vinita Gupta, benoemd in Sep2013, heeft een ambtstermijn van 11.08 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 235.59M, bestaande uit 59.9% salaris en 40.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.072% van de aandelen van het bedrijf, ter waarde ₹ 717.11M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 4.2 jaar.

Belangrijke informatie

Vinita Gupta

Algemeen directeur

₹235.6m

Totale compensatie

Percentage CEO-salaris	59.9%
Dienstverband CEO	11.1yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Vinita Gupta's beloning veranderd ten opzichte van Lupin's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	₹23b
Mar 31 2024	₹236m	₹141m	₹19b
Dec 31 2023	n/a	n/a	₹18b
Sep 30 2023	n/a	n/a	₹13b
Jun 30 2023	n/a	n/a	₹10b
Mar 31 2023	₹109m	₹78m	₹4b
Dec 31 2022	n/a	n/a	-₹3b
Sep 30 2022	n/a	n/a	₹682m
Jun 30 2022	n/a	n/a	-₹22b
Mar 31 2022	₹145m	₹145m	-₹15b
Dec 31 2021	n/a	n/a	-₹5b
Sep 30 2021	n/a	n/a	-₹7b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹128m	₹92m	₹12b
Dec 31 2020	n/a	n/a	₹11b
Sep 30 2020	n/a	n/a	-₹2b
Jun 30 2020	n/a	n/a	-₹6b
Mar 31 2020	₹128m	₹93m	-₹4b
Dec 31 2019	n/a	n/a	-₹4b
Sep 30 2019	n/a	n/a	₹3b
Jun 30 2019	n/a	n/a	₹7b
Mar 31 2019	₹15m	₹49m	₹5b
Dec 31 2018	n/a	n/a	-₹5b
Sep 30 2018	n/a	n/a	-₹931m
Jun 30 2018	n/a	n/a	₹960m
Mar 31 2018	₹172m	₹123m	₹3b

Compensatie versus markt: Vinita's total compensation ($USD2.81M) is above average for companies of similar size in the Indian market ($USD1.09M).

Compensatie versus inkomsten: Vinita's compensation has increased by more than 20% in the past year.

CEO

Vinita Gupta (56 yo)

11.1yrs

Tenure

₹235,590,000

Compensatie

Ms. Vinita D. Gupta has been the Chief Executive Officer at Lupin Limited since September 1, 2013. Ms. Gupta serves as an Executive Director of Lupin Limited. She has been the Chairman and Chief Executive...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Vinita Gupta	CEO & Executive Director	11.1yrs	₹235.59m	0.072% ₹ 718.4m
Ramesh Swaminathan	Executive Director	4.6yrs	₹81.69m	0.00049% ₹ 4.9m
Nilesh Gupta	MD & Executive Director	no data	₹95.78m	0.22% ₹ 2.2b
Christoph Funke	Chief Technical Operations Officer	less than a year	geen gegevens	geen gegevens
Sreeji Gopinathan	Chief Information Officer	5yrs	geen gegevens	geen gegevens
Shahin Fesharaki	Global Chief Scientific Officer	2yrs	geen gegevens	geen gegevens
Ravi Agrawal	Sr. Vice President of Investor Relations and M&A	no data	geen gegevens	geen gegevens
Sofia Mumtaz	President of Legal and Compliance of Australia	no data	geen gegevens	geen gegevens
Amit Gupta	Company Secretary & Compliance Officer	less than a year	geen gegevens	geen gegevens
Rajalakshmi Azariah	Vice President & Global Head of Corporate Communications	no data	geen gegevens	geen gegevens
Fabrice Egros	President of Global Corporate Development & Growth Markets	2.7yrs	geen gegevens	geen gegevens
Yashwant Mahadik	President of Global Human Resources	6.3yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: 500257's management team is considered experienced (3.6 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Vinita Gupta	CEO & Executive Director	no data	₹235.59m	0.072% ₹ 718.4m
Ramesh Swaminathan	Executive Director	4.6yrs	₹81.69m	0.00049% ₹ 4.9m
Nilesh Gupta	MD & Executive Director	16yrs	₹95.78m	0.22% ₹ 2.2b
Mark McDade	Independent Director	3.8yrs	₹15.52m	geen gegevens
Jean-Luc Belingard	Independent Non-Executive Director	9yrs	₹15.46m	geen gegevens
Kanwar Bir Anand	Independent Director	4.2yrs	₹15.59m	geen gegevens
Alfonso Zulueta	Independent Director	less than a year	geen gegevens	geen gegevens
Manju Gupta	Non-Executive Chairman of the Board	41.6yrs	₹8.87m	0.90% ₹ 9.0b
Punita Sinha	Independent Director	4.2yrs	₹15.62m	0.00011% ₹ 1.1m
Jeffrey Kindler	Independent Director	less than a year	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: 500257's board of directors are considered experienced (4.2 years average tenure).

Lupin Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Lupin Limited Announces Change of Company Secretary and Compliance Officer

Lupin Limited, Annual General Meeting, Aug 02, 2024

Lupin Limited Announces Board Appointments

Lupin Limited Announces Change in Management

Insufficient new directors

Lupin Limited, Annual General Meeting, Aug 03, 2023

Recent updates

Consensus EPS estimates increase by 11%

Price target increased by 12% to ₹1,835

Lupin Limited Announces Change of Company Secretary and Compliance Officer

Lupin Limited Approves Dividend for Year Ended March 31, 2024

Lupin Limited to Report Q1, 2025 Results on Aug 06, 2024

Dividend increased to ₹8.00

Lupin Limited, Annual General Meeting, Aug 02, 2024

Lupin Limited Announces Board Appointments

Full year 2024 earnings: EPS misses analyst expectations

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Lupin Limited Announces Change in Management

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Consensus EPS estimates increase by 14%

Price target increased by 7.3% to ₹1,058

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla in Spain for the Symptomatic Treatment of Myotonia in Adults with Non-Dystrophic Myotonic Disorders

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

Lupin Limited Launches Novel Fixed-Dose Triple Drug Combination Difizma® Dpi to Treat Inadequately Controlled Asthma

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

Lupin Launches Rufinamide Tablets USP in the United States

Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

Consensus forecasts updated

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules

Lupin Limited Receives Tentative Approval from U.S. FDA for Drospirenone Tablets

Lupin Limited Update on its Biotech Manufacturing Facility

Lupin Announces Resignation of Kamal K. Sharma from the Board of Directors

Lupin Limited Appoints Shahin Fesharaki as Global Chief Scientific Officer

Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets

Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w

Lupin Receives Health Canada Approval for Rymti® (Biosimilar Etanercept)

Lupin Launches Generic Suprep® Bowel Prep Kit in the United States

Lupin Limited in Partnership with Pharmascience Inc. Receives Tentative Approval from U.S. Fda for Dasatinib Tablets

Lupin Limited Announces Launch of Desvenlafaxine Extended-Release Tablets, 25 Mg

Lupin Limited (BSE:500257) agreed to acquire Ondero and Ondero - Met from Boehringer Ingelheim International GmbH for €26 million.

Lupin Limited Receives Approval from U.S. FDA for Rufinamide Tablets USP